10-Q: Denali Capital Acquisition Corp. Reports Net Income of $264,330 for Q1 2024 Amidst Business Combination Efforts

Denali Capital Acquisition Corp. announced a net income of $264,330 for the first quarter of 2024, primarily driven by investment income, while continuing efforts to finalize its business combination with Longevity Biomedical, Inc.

Summary

• Denali Capital Acquisition Corp., a blank check company, reported a net income of $264,330 for the quarter ended March 31, 2024, a significant improvement compared to a net loss of $1,009,102 for the same period in 2023.
• The company's income was primarily driven by $653,885 in income from its Trust Account, which holds proceeds from its initial public offering (IPO).
• Operating expenses for the quarter totaled $368,252, and interest expenses were $21,303.
• The company is in the process of completing a business combination with Longevity Biomedical, Inc., which was approved by shareholders on January 9, 2024.
• As of March 31, 2024, the company held $51,281,849 in its Trust Account and had a working capital deficit of $5,934,095.
• The company has extended the deadline to complete a business combination to July 11, 2024, with potential monthly extensions, and has received additional funding through convertible promissory notes.
• The company received a notification from Nasdaq regarding non-compliance with listing rules due to its Minimum Value of Listed Securities (MVLS) falling below $50 million and not meeting the minimum asset and revenue requirements, and has until August 20, 2024, to regain compliance.

Sentiment

Score: 4

Explanation: The document presents a mixed picture with positive net income for the quarter but significant concerns about working capital, Nasdaq compliance, and the ability to continue as a going concern. The need for additional funding and the uncertainty surrounding the business combination contribute to a negative sentiment.

Positives

• The company generated a net income of $264,330 for the quarter, a significant improvement from the previous year.
• The Trust Account generated substantial income, contributing to the company's positive financial results.
• Shareholders have approved the proposed business combination with Longevity Biomedical, Inc.
• The company has secured additional funding through convertible promissory notes to support its operations and business combination efforts.

Negatives

• The company has a significant working capital deficit of $5,934,095.
• The company received a notification from Nasdaq for non-compliance with listing rules due to its MVLS falling below $50 million.
• The company's ability to continue as a going concern is in doubt through July 11, 2024, if a business combination is not completed.
• The company has incurred significant formation and operating costs.

Risks

• The company's ability to continue as a going concern is uncertain if a business combination is not completed by July 11, 2024, subject to monthly extensions.
• The company faces the risk of delisting from Nasdaq if it does not regain compliance with listing rules by August 20, 2024.
• The company has a working capital deficit, which may require additional financing.
• The ongoing military action in Ukraine and hostilities in the Middle East could have an undetermined impact on the company's financial condition.
• There is no assurance that the business combination with Longevity will be completed.

Future Outlook

The company is working to complete the business combination with Longevity Biomedical, Inc. and is seeking to regain compliance with Nasdaq listing rules. The company may need to raise additional capital to complete the business combination and fund operations.

Management Comments

• Management believes that the company will not have sufficient working capital and borrowing capacity to meet its needs through the consummation of the initial business combination.
• Management intends to actively monitor the company's MVLS and evaluate options to resolve the deficiency and regain compliance with the Nasdaq listing requirements.

Industry Context

The document reflects the typical challenges faced by SPACs, including the need to complete a business combination within a specified timeframe, manage redemptions, and maintain listing compliance. The company's focus on technology, consumer, and hospitality sectors is consistent with current market trends.

Comparison to Industry Standards

• The financial performance of Denali Capital Acquisition Corp. is typical for a SPAC in its pre-merger phase, with minimal operating revenue and reliance on investment income from the Trust Account.
• The company's working capital deficit is a common issue for SPACs, which often rely on additional financing to complete their business combinations.
• The notification of non-compliance from Nasdaq is not uncommon for SPACs that have experienced significant redemptions and a decline in share price.
• The company's reliance on convertible promissory notes for funding is a common practice among SPACs seeking to extend their operational runway.
• Compared to other SPACs, Denali's situation is not unique, as many face similar challenges in securing a target and maintaining listing compliance. For example, companies like Churchill Capital Corp IV (CCIV) and Social Capital Hedosophia Holdings Corp V (IPOE) have faced similar issues with redemptions and share price volatility.

Related Party Transactions

• The company has entered into several related party transactions, including loans from the sponsor and FutureTech in the form of convertible promissory notes.
• The sponsor has agreed to cover certain liabilities if claims reduce the Trust Account below a certain level.

Stakeholder Impact

• Shareholders face the risk of potential losses if the business combination is not completed or if the company is delisted from Nasdaq.
• The company's employees and management are impacted by the uncertainty surrounding the company's future.
• The company's creditors are exposed to the risk of non-payment if the company is unable to continue as a going concern.

Next Steps

• The company needs to complete the business combination with Longevity Biomedical, Inc.
• The company must regain compliance with Nasdaq listing rules by August 20, 2024.
• The company may need to secure additional financing to support its operations and complete the business combination.

Key Dates

Keywords

business combination, SPAC, Longevity Biomedical, Trust Account, Nasdaq, convertible promissory notes, working capital, redemption, merger, financial results